Nicola S. Meagher
YOU?
Author Swipe
View article: Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma Open
BRCA-associated homologous recombination deficiency (HRD) is present in ~ 50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA-…
View article: A 5‐marker immunohistochemical panel of <scp>CK17</scp>, <scp>MEP1A</scp>, <scp>PAX8</scp>, <scp>SMAD4</scp>, and <scp>CDX2</scp> to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma
A 5‐marker immunohistochemical panel of <span>CK17</span>, <span>MEP1A</span>, <span>PAX8</span>, <span>SMAD4</span>, and <span>CDX2</span> to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma Open
Aims Metastatic pancreatic adenocarcinoma (PDAC), albeit uncommon, may involve the ovary, and distinction from primary ovarian mucinous tumours (OMT) poses a diagnostic challenge. Our aim was to develop an ancillary immunohistochemical (IH…
View article: Cellular origins of mucinous ovarian carcinoma
Cellular origins of mucinous ovarian carcinoma Open
Mucinous ovarian carcinoma (MOC) is a rare histotype of epithelial ovarian cancer. Its origins are obscure: while many mucinous tumours in the ovary are metastases from the gastrointestinal tract, MOC can occur as an ovarian primary; howev…
View article: Sociodemographic and health factors associated with genetic testing in Australia: insights from a cohort-based study of 45,061 participants
Sociodemographic and health factors associated with genetic testing in Australia: insights from a cohort-based study of 45,061 participants Open
With increasing availability of genetic tests, it is important to consider differences in testing patterns between population subgroups. We examined self-reported genetic testing among 45,061 participants of the Australian population-based…
View article: Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer Open
BACKGROUNDDespite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment.METHODSWe evaluated the tumor microenvironment of this…
View article: Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S4. Differential gene expression analysis comparing transcriptomes of tumors based on BRCA and RB1 alteration status.
View article: Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S10 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S10. Immune cell subsets inferred from gene expression data by combined homologous recombination deficiency and RB1 status.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S3. Number of RNA-seq primary tumor samples by library type and alteration group.
View article: Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S9. Bars indicate the number of differentially expressed genes (Benjamini-Hochberg adjusted P value < 0.05) between HGSC tumors grouped by HRD and/or RB1 status as shown.
View article: Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S8 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S8. Antibodies and reagents.
View article: Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Multivariate analysis of molecular alterations and OS in patients with HGSC and ENOC.
View article: Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Clinicopathologic characteristics and RB1 expression patterns across histotypes.
View article: Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S6 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S6. Mutational signatures in homologous recombination deficiency and RB1 subgroups.
View article: Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S1. Details of participating Ovarian Tumor Tissue Analysis (OTTA) consortium studies and ethics approvals.
View article: Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
View article: Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S4 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.
View article: Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S3. Overall survival by combined RB1 and p53 expression in ENOC, and RB1 protein expression and BRCA status in HGSC.
View article: Supplementary Figure S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S1. Patients and tumor samples analyzed in this study.
View article: Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S9 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Figure S9. Bars indicate the number of differentially expressed genes (Benjamini-Hochberg adjusted P value < 0.05) between HGSC tumors grouped by HRD and/or RB1 status as shown.
View article: Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S3 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S3. Number of RNA-seq primary tumor samples by library type and alteration group.
View article: Supplementary Table S11 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S11 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S11. Multivariable adjusted association of molecular alterations and overall survival in HGSC and ENOC among patients with residual disease* status.
View article: Supplementary Table S16 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S16 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S16. Median survival according to germline BRCA1 and BRCA2 status by RB1 protein expression.
View article: Supplementary Table S19 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S19 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S19. Relative expression of BRCA1 and RB1 by qPCR in AOCS30 CRISPR knockout model.
View article: Supplementary Table S15 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S15 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S15. Clinical characteristics of patients with HGSC according to RB1 and BRCA status.
View article: Supplementary Table S2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S2. Molecular and clinical data summary of 126 patients in the Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG) study.
View article: Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Table 2 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Multivariate analysis of molecular alterations and OS in patients with HGSC and ENOC.
View article: Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma Open
Supplementary Table S1. Details of participating Ovarian Tumor Tissue Analysis (OTTA) consortium studies and ethics approvals.